This is one of two studies published in the Lancet Oncology that report negative findings with use of dacomitinib, an irreversible pan-EGFR family tyrosine kinase inhibitor, in the treatment of non-small-cell lung cancer. A Comment article suggests that “in this era of new treatment strategies, including immunotherapy, use of EGFR tyrosine kinase inhibitors in EGFR wild-type advanced non-small-cell lung cancer should be restricted to erlotinib in its indication defined 10 years ago in the BR.21 trial, where only a small improvement over best supportive care in clinical outcome should be expected.”